Terms ending in 2028
Every in-force patent on GlaxoSmithKline LLC's record whose computed term ends in 2028, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US RE44,613 | N-Substituted Glycine Derivatives: Hydroxylase Inhibitors In force · Low confidence | GlaxoSmithKline LLC | In force | Low confidence | |
| US 8,022,032 | Method for Customized Dispensing of Variable Dose Drug Combination Products for Individualizing of Therapies In force · High confidence | GlaxoSmithKline LLC | In force | High confidence | |
| US 8,946,278 | INHIBITORS OF AkT ACTIVITY In force · High confidence | Novartis AG | In force | High confidence | |
| US 8,637,563 | A Non-Peptide Thrombopoietin Receptor Agonist in the Treatment of Cancer and Pre-Cancerous Syndromes In force · Medium confidence | Novartis AG | In force | Medium confidence | |
| US 7,902,394 | Calcilytic Compounds In force · High confidence | GlaxoSmithKline LLC | In force | High confidence | |
| US 9,597,294 | Continuous Coating of Pellets In force · High confidence | GlaxoSmithKline LLC | In force | High confidence | |
| US 9,238,628 | Phenyl Amino Pyrimidine Compounds and Uses Thereof In force · High confidence | GlaxoSmithKline LLC | In force | High confidence | |
| US 12,570,614 | Phenyl Amino Pyrimidine Compounds and Uses Thereof In force · High confidence | GlaxoSmithKline LLC | In force | High confidence | |
| US D701,957 | Nasal Dilator In force · Medium confidence | GlaxoSmithKline LLC | In force | Medium confidence | |
| US D703,318 | Nasal Dilator In force · High confidence | GlaxoSmithKline LLC | In force | High confidence | |
| 11 more term ends in 2028 · Pro | |||||
10 of 21 patents shown. Soonest term end first, then patent number.
Pro members see all 21, including 11 expiring within the 18 months from Nov 19, 2026.
15 of these are in force and held by GlaxoSmithKline LLC.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.